OPEN PROSPECTIVE TRIAL INVESTIGATING PHARMACOKINETICS, TOLERABILITY AND SAFETY OF A NEW 10% HUMAN IMMUNOGLOBULIN FOR INTRAVENOUS INFUSION (IVIG) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE

被引：0
|
作者：
Krivan, G. [1 ]
Koenigs, C. [2 ]
Bernatowska, E. [3 ]
Marodi, L. [4 ]
Erdos, M. [4 ]
Salama, A. [5 ]
Linde, R. [2 ]
机构：
[1] United St Istvan & St Laszlo Hosp, Dept Pediat Hematol & Stem Cell Transplantat, Budapest, Hungary
[2] Goethe Univ Frankfurt, Dept Pediat Hemostasis & Immunodeficiency, Frankfurt, Germany
[3] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland
[4] Univ Debrecen, Med & Hlth Sci Ctr, Dept Infectol & Pediat Immunol, H-4012 Debrecen, Hungary
[5] Univ Med Berlin, Inst Transfus Med, Berlin, Germany
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2012年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics, Efficacy, Tolerability and Safety of a New Subcutaneous Human Immunoglobulin 16.5% in Primary Immune Deficiency
    Kobayashi, Roger
    Gupta, Sudhir
    Melamed, Isaac R.
    Mandujano, Jose F.
    Kobayashi, Ai Lan
    Ritchie, Bruce
    Turpel-Kantor, Eva
    Litzman, Jiri
    JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (03) : 391 - 392
  • [32] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PI)
    Stein, M.
    Wasserman, R. L.
    Melamed, I.
    Rubinstein, A.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 135 - 136
  • [33] Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin:: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies
    Wolf, HH
    Davies, SV
    Borte, M
    Caulier, MT
    Williams, PE
    Bernuth, HV
    Egner, W
    Sklenar, I
    Adams, C
    Späth, P
    Morell, A
    Andresen, I
    VOX SANGUINIS, 2003, 84 (01) : 45 - 53
  • [34] A prospective multicenter safety surveillance study with a 5% intravenous human immunoglobulin (IVIg) preparation, in patients suitable for IVIg treatment, with or without premedication
    Peinert, S.
    Abenhardt, W.
    Fenchel, K.
    Huebner, A.
    Reichert, D.
    Scheidegger, C.
    Schmidt, A.
    von Wussow, P.
    Galic, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 85 - 86
  • [35] Efficacy, Pharmacokinetics and Safety of I10, a Novel 10 % Intravenous Immunoglobulin in Patients with Primary Immune Deficiency (PID): a Prospective Multicentre Study
    Krivan, Gergely
    Chernyshova, Ludmila
    Kostyuchenko, Larysa
    Lange, Andrzej
    Nyul, Zoltan
    Derfalvi, Beata
    Musial, Jacek
    Bellon, Anne
    Kappler, Martin
    Sadoun, Alain
    Bernatowska, Ewa
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 : S47 - S48
  • [36] Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
    Sudhir Gupta
    James DeAngelo
    Isaac Melamed
    Jolan E. Walter
    Ai-Lan Kobayashi
    Tracy Bridges
    J. Wesley Sublett
    Jonathan A. Bernstein
    Alan Koterba
    Michael Manning
    Joanna Maltese
    Sonja Hoeller
    Eva Turpel-Kantor
    Huub Kreuwel
    Roger H. Kobayashi
    Journal of Clinical Immunology, 2023, 43 : 1414 - 1425
  • [37] Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
    Gupta, Sudhir
    DeAngelo, James
    Melamed, Isaac
    Walter, Jolan E. E.
    Kobayashi, Ai-Lan
    Bridges, Tracy
    Sublett, J. Wesley
    Bernstein, Jonathan A. A.
    Koterba, Alan
    Manning, Michael
    Maltese, Joanna
    Hoeller, Sonja
    Turpel-Kantor, Eva
    Kreuwel, Huub
    Kobayashi, Roger H. H.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2023, 43 (06) : 1414 - 1425
  • [38] Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease
    Jennifer Heimall
    Junliang Chen
    Joseph A. Church
    Rhonda Griffin
    Isaac Melamed
    Gary I. Kleiner
    Journal of Clinical Immunology, 2016, 36 : 600 - 609
  • [39] Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEXA®-C) in Pediatric Patients with Primary Immunodeficiency Disease
    Heimall, Jennifer
    Chen, Junliang
    Church, Joseph A.
    Griffin, Rhonda
    Melamed, Isaac
    Kleiner, Gary I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (06) : 600 - 609
  • [40] New 10% liquid intravenous immunoglobulin for treatment of multifocal motor neuropathy: a prospective study of efficacy, safety and tolerability
    Cats, E. A.
    van der Pol, W. L.
    van den Berg-Vos, R. M.
    Wokke, J. H. J.
    Franssen, H.
    van den Berg, L. H.
    JOURNAL OF NEUROLOGY, 2008, 255 : 105 - 106
12345